Demographic background and clinical characteristics of enrolled patients for modelling
| Characteristics | Number or mean±SD | Median (range) |
| No. Patients | 51 | – |
| No. Observations | 196 | – |
| Observations per patient | 3.84 | – |
| No. Male/Female | 33/18 | – |
| No. AKI | 20 (39.21%) | – |
| No. Hepatic insufficiency | 26 (50.98%) | – |
| No. Sepsis shock | 18 (35.29%) | – |
| No. Ventilation | 26 (50.98%) | – |
| No. Respiratory infection | 27 (52.94%) | – |
| No. Bloodstream infection | 2 (0.04%) | – |
| No. Other infection | 22 (43.14%) | – |
| Course of treatment (d) | 9.35±3.94 | 9 (3-19) |
| Dose (mg) | 519.61±97.05 | 500 (500–1000) |
| Daily dose (mg) | 2032.26±286.80 | 2000 (1500–3000) |
| Age (year) | 56.45±18.76 | 56 (18–96) |
| Body weight (kg) | 70.21±72.01 | 69 (19.6–311.7) |
| Cr (μmol/L) | 94.35±187.94 | 64.8 (32.8–883) |
| CrCl (mL/min) | 104.59±60.95 | 99.34 (17.80–256.22) |
| APACHE II score | 16.67±6.44 | 15 (8–33) |
| SOFA | 6.78±5.06 | 5 (2-19) |
Hepatic insufficiency: Child-Pugh B&C.
Sepsis shock: Compliance with diagnostic criteria of sepsis 3.0.
By measuring the serum creatinine level, the Cockcroft formula was used to calculate the endogenous creatinine clearance (CrCl), CrCl = [(140-age) × weight (kg)] / [0.818×Cr (μmol / L)]. For women, the calculation result × 0.85.
AKI, Acute Kidney Injury, Compliance with Kidney Disease: Improving Global Outcomes (KDIGO) AKI Guideline 2021; APACHE, Acute Physiology and Chronic Health Evaluation; Cr, Serum Creatinine; CrCl, Serum Creatinine Clearance; SOFA, Sequential Organ Failure Assessment.